QualityStocksNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Featured in BioMedWire Editorial on Multiple Sclerosis Treatment
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced that it is featured in a BioMedWire editorial examining the need for new approaches to treating multiple sclerosis ("MS"), a progressive neurological disease affecting more than 2.9 million people worldwide. The editorial, titled "The Quest to Repair What Multiple Sclerosis Takes Away," highlights the limitations of current therapies, which can slow disease progression but cannot stop it completely. The editorial discusses Quantum BioPharma's development of Lucid-MS, a patented, first-in-class drug candidate designed to directly target the myelin sheath damaged by MS. The company said the potential therapy is preparing to advance…